SECONDARY MALIGNANCIES OF T-CELL ORIGIN

Clinical trials for SECONDARY MALIGNANCIES OF T-CELL ORIGIN explained in plain language.

Never miss a new study

Get alerted when new SECONDARY MALIGNANCIES OF T-CELL ORIGIN trials appear

Sign up with your email to follow new studies for SECONDARY MALIGNANCIES OF T-CELL ORIGIN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Long-Term safety check: does a pioneering cancer treatment carry a hidden risk?

Knowledge-focused Not yet recruiting

This study aims to understand if a specific CAR-T cell therapy (tisagenlecleucel) could be linked to patients developing a second, different type of T-cell cancer later on. It will analyze existing tissue and blood samples from about 30 people who received the therapy and were la…

Matched conditions: SECONDARY MALIGNANCIES OF T-CELL ORIGIN

Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused

Last updated Mar 13, 2026 15:06 UTC

SECONDARY MALIGNANCIES OF T-CELL ORIGIN

Get alerted when new SECONDARY MALIGNANCIES OF T-CELL ORIGIN trials appear

Long-Term safety check: does a pioneering cancer treatment carry a hidden risk?